SG10201909188XA - Novel therapies for cancer - Google Patents
Novel therapies for cancerInfo
- Publication number
- SG10201909188XA SG10201909188XA SG10201909188XA SG10201909188XA SG 10201909188X A SG10201909188X A SG 10201909188XA SG 10201909188X A SG10201909188X A SG 10201909188XA SG 10201909188X A SG10201909188X A SG 10201909188XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- novel therapies
- treatment
- relates
- diazepan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141980P | 2015-04-02 | 2015-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201909188XA true SG10201909188XA (en) | 2019-11-28 |
Family
ID=55702039
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707429VA SG11201707429VA (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
| SG10201909188X SG10201909188XA (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707429VA SG11201707429VA (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11311552B2 (zh) |
| EP (1) | EP3277284B1 (zh) |
| JP (1) | JP6927882B2 (zh) |
| KR (1) | KR20170132314A (zh) |
| CN (2) | CN112569242A (zh) |
| AU (1) | AU2016242118B2 (zh) |
| BR (1) | BR112017019437A2 (zh) |
| CA (1) | CA2979167A1 (zh) |
| DK (1) | DK3277284T3 (zh) |
| EA (1) | EA037555B1 (zh) |
| ES (1) | ES2826558T3 (zh) |
| HK (1) | HK1245120A1 (zh) |
| HU (1) | HUE051341T2 (zh) |
| IL (1) | IL254149A0 (zh) |
| MX (1) | MX2017011981A (zh) |
| PL (1) | PL3277284T3 (zh) |
| PT (1) | PT3277284T (zh) |
| SG (2) | SG11201707429VA (zh) |
| WO (1) | WO2016157149A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| ES2826558T3 (es) | 2015-04-02 | 2021-05-18 | Proximagen Llc | Nuevas terapias para el cáncer |
| GB201604213D0 (en) | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| GB201703907D0 (en) * | 2017-03-10 | 2017-04-26 | Proximagen Ltd | Novel therapies for cancer |
| WO2020222189A1 (en) | 2019-05-02 | 2020-11-05 | Proximagen, Llc | Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide |
| WO2020222190A1 (en) | 2019-05-02 | 2020-11-05 | Proximagen, Llc | Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047406A (en) | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| FR2769913B1 (fr) | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| EP1294704A1 (en) | 2000-06-29 | 2003-03-26 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| AR036366A1 (es) | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| WO2003082855A1 (fr) | 2002-03-28 | 2003-10-09 | Kyowa Hakko Kogyo Co., Ltd. | Agent anti-inflammatoire |
| US7759336B2 (en) | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| JP2006524242A (ja) * | 2003-03-27 | 2006-10-26 | エモリー ユニバーシティー | Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法 |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| FR2854633B1 (fr) | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| EP1708703A4 (en) | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006088836A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| MX2007009946A (es) | 2005-02-16 | 2007-09-26 | Schering Corp | Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3. |
| ATE523506T1 (de) | 2005-02-16 | 2011-09-15 | Schering Corp | Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität |
| US7417045B2 (en) | 2005-02-16 | 2008-08-26 | Schering Corporation | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity |
| CA2598458A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| WO2006130426A2 (en) | 2005-05-27 | 2006-12-07 | Kemia, Inc. | Modulators of ccr-5 activity |
| GB0525957D0 (en) | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| KR20080106970A (ko) | 2006-03-21 | 2008-12-09 | 쉐링 코포레이션 | Ｃｘｃｒ３ 길항제 활성을 갖는 헤테로사이클릭 치환된 피리딘 화합물 |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| AU2007272884A1 (en) | 2006-07-14 | 2008-01-17 | Pharmacopeia, Inc. | Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity |
| JP5606736B2 (ja) | 2006-09-02 | 2014-10-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 反応性メソゲンを配向するための粒子ビーム法 |
| PL2066662T3 (pl) | 2006-09-21 | 2013-05-31 | Kyorin Seiyaku Kk | Inhibitory hydrolaz serynowych |
| JP2010510224A (ja) | 2006-11-17 | 2010-04-02 | アボット・ラボラトリーズ | ケモカイン受容体拮抗薬としてのアミノピロリジン類 |
| JP2010513520A (ja) | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する複素環式化合物 |
| NZ578744A (en) | 2007-01-31 | 2012-02-24 | Vertex Pharma | 2-aminopyridine derivatives useful as kinase inhibitors |
| WO2008121065A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel pyrrolidine derivatives as antagonists of the chemokine receptor |
| PT2231636E (pt) | 2007-12-07 | 2012-01-02 | Novartis Ag | Derivados de pirazole e a sua utilização a título de inibidores de quinases dependentes de ciclina |
| EP2262494A2 (en) * | 2008-02-29 | 2010-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis |
| KR101701367B1 (ko) | 2008-11-04 | 2017-02-02 | 케모센트릭스, 인크. | Ｃｘｃｒ７의 모듈레이터 |
| MX2012000709A (es) | 2009-07-15 | 2012-03-16 | Abbott Lab | Inhibidores de pirrolopiridina de cinasas. |
| KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| WO2012047339A2 (en) * | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| GB201017048D0 (en) * | 2010-10-08 | 2010-11-24 | Ucl Business Plc | Composition |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| JP6321673B2 (ja) * | 2012-12-20 | 2018-05-09 | ルゥ チーン−ビン | 放射線と組み合わせて使用するための放射線増感剤化合物 |
| ES2826558T3 (es) | 2015-04-02 | 2021-05-18 | Proximagen Llc | Nuevas terapias para el cáncer |
| GB201604213D0 (en) | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| GB201703907D0 (en) | 2017-03-10 | 2017-04-26 | Proximagen Ltd | Novel therapies for cancer |
-
2016
- 2016-04-01 ES ES16715626T patent/ES2826558T3/es active Active
- 2016-04-01 AU AU2016242118A patent/AU2016242118B2/en not_active Expired - Fee Related
- 2016-04-01 BR BR112017019437A patent/BR112017019437A2/pt not_active Application Discontinuation
- 2016-04-01 CN CN202011468330.5A patent/CN112569242A/zh active Pending
- 2016-04-01 CN CN201680020617.7A patent/CN107438437B/zh not_active Expired - Fee Related
- 2016-04-01 CA CA2979167A patent/CA2979167A1/en not_active Abandoned
- 2016-04-01 MX MX2017011981A patent/MX2017011981A/es unknown
- 2016-04-01 EA EA201791953A patent/EA037555B1/ru unknown
- 2016-04-01 EP EP16715626.4A patent/EP3277284B1/en active Active
- 2016-04-01 DK DK16715626.4T patent/DK3277284T3/da active
- 2016-04-01 SG SG11201707429VA patent/SG11201707429VA/en unknown
- 2016-04-01 JP JP2017548463A patent/JP6927882B2/ja active Active
- 2016-04-01 SG SG10201909188X patent/SG10201909188XA/en unknown
- 2016-04-01 HU HUE16715626A patent/HUE051341T2/hu unknown
- 2016-04-01 US US15/562,741 patent/US11311552B2/en active Active
- 2016-04-01 KR KR1020177031648A patent/KR20170132314A/ko not_active Application Discontinuation
- 2016-04-01 PL PL16715626T patent/PL3277284T3/pl unknown
- 2016-04-01 WO PCT/IB2016/051880 patent/WO2016157149A1/en active Application Filing
- 2016-04-01 PT PT167156264T patent/PT3277284T/pt unknown
-
2017
- 2017-08-24 IL IL254149A patent/IL254149A0/en unknown
-
2018
- 2018-04-10 HK HK18104660.1A patent/HK1245120A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3277284T3 (pl) | 2021-03-08 |
| AU2016242118A1 (en) | 2017-10-05 |
| EA037555B1 (ru) | 2021-04-13 |
| CN112569242A (zh) | 2021-03-30 |
| EP3277284B1 (en) | 2020-08-05 |
| CN107438437B (zh) | 2021-01-01 |
| MX2017011981A (es) | 2018-01-10 |
| US20180078563A1 (en) | 2018-03-22 |
| SG11201707429VA (en) | 2017-10-30 |
| IL254149A0 (en) | 2017-10-31 |
| JP2018510154A (ja) | 2018-04-12 |
| EP3277284A1 (en) | 2018-02-07 |
| ES2826558T3 (es) | 2021-05-18 |
| US11311552B2 (en) | 2022-04-26 |
| WO2016157149A9 (en) | 2016-12-08 |
| AU2016242118B2 (en) | 2021-07-08 |
| JP6927882B2 (ja) | 2021-09-01 |
| CN107438437A (zh) | 2017-12-05 |
| DK3277284T3 (da) | 2020-10-26 |
| BR112017019437A2 (pt) | 2018-05-02 |
| WO2016157149A1 (en) | 2016-10-06 |
| CA2979167A1 (en) | 2016-10-06 |
| KR20170132314A (ko) | 2017-12-01 |
| HK1245120A1 (zh) | 2018-08-24 |
| PT3277284T (pt) | 2020-11-11 |
| EA201791953A1 (ru) | 2018-01-31 |
| HUE051341T2 (hu) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201909188XA (en) | Novel therapies for cancer | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| SI3640251T1 (sl) | Derivati 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| IL287889A (en) | Administration of transgenic t cells for the treatment of central nervous system cancer | |
| MA39906A (fr) | Polythérapies pour le traitement du cancer | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2018000216A (es) | Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos. | |
| MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
| MD4801C1 (ro) | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| MX2018001289A (es) | Terapias de combinacion para el tratamiento del cancer. | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| PH12017500881B1 (en) | Aurora a kinase inhibitor | |
| MX2018011975A (es) | Terapia de combinacion para tratamiento de leucemia mieloide aguda. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| MX2019010679A (es) | Usl-311 para uso en el tratamiento de cancer. | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| NZ722296A (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |